SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations.

Slides:

Advertisements

Similar presentations

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Quality of Life After Treatment of Laryngeal.

Advertisements

Volume 160, Issue 5, Pages (November 2016)

Triangles and dotted lines are for mean values. , P <

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.

Volume 7, Issue 2, Pages (February 2015)

Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients who were rescued or discontinued.

Lung Resection Improves the Quality of Life of Patients With Symptomatic Bronchiectasis Camilla Carlini Vallilo, MS, Ricardo Mingarini Terra, MD, PhD,

Health-Related Quality-of-Life Measures: Evidence from Tunisian Population Using the SF-12 Health Survey Moheddine Younsi, PhD Value in Health Regional.

Volume 61, Issue 5, Pages (November 2014)

The Impact of Pain Management on Quality of Life

Five-year real world outcomes of GeoForm ring implantation in patients with ischemic mitral regurgitation Tomasz A. Timek, MD, Robert L. Hooker, MD,

Effects of deep hypothermic circulatory arrest on outcome after resection of ascending aortic aneurysm Franz F Immer, MD, Hanna Barmettler, MD, Pascal.

Baseline Comorbidity Associated With the Short-Term Effects of Exercise Intervention on Quality of Life in the Japanese Older Population: An Observational.

Health-Related Quality of Life Outcome After On-Pump Versus Off-Pump Coronary Artery Bypass Graft Surgery: A Prospective Randomized Study Reza Motallebzadeh,

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Cardiac Reoperation in Patients Aged 80 Years and Older

Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement J.M. Quintana, Ph.D., A. Escobar, M.D., A. Bilbao,

Health Status Rated With the Medical Outcomes Study 36-Item Short-Form Health Survey After Spinal Cord Injury Mark J. Haran, Bonsan B. Lee, Madeleine.

Volume 44, Issue 3, Pages (March 2006)

Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement A. Escobar, M.D., J.M. Quintana, Ph.D., A. Bilbao,

Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity Nina K. Grewal,

Long-Term Health-Related Quality of Life After Maze Surgery for Atrial Fibrillation Catharina Lundberg, MD, Anders Albåge, MD, PhD, Carina Carnlöf, RN,

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Comparison of recovery after mitral valve repair and replacement

Mu Qin et al. JACEP 2017;j.jacep

(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.

Patient disposition through 48 weeks in RA-BEYOND

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Health-related quality of life in survivors of open ruptured abdominal aortic aneurysm repair: A matched, controlled cohort study Andrew B. Hill, MDCM,

Seth D. Crockett, Quinn K. Lippmann, Evan S. Dellon, Nicholas J

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Percentage of patients reporting improvements ≥MCID and NNTs to achieve an MCID in (A) PtGA, (B) pain, (C) HAQ-DI, (D) FACIT-F and (E) SF-36 domains and.

Switching of biological agents (BAs), and achievement of inactive disease and clinical remission (CR). Switching of biological agents (BAs), and achievement.

Mean individual and summative SF-36 V2 scores before and 3 months after ablation. Mean individual and summative SF-36 V2 scores before and 3 months after.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Clinical response in patients with early and established RA at month 24. *p

Patient-reported quality of life after abdominal aortic aneurysm surgery: A prospective comparison of endovascular and open repair Badr Aljabri, MD,

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

Percentage of patients with RA achieving DAS28(CRP)<2

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form.

Spydergram of mean SF-36 domain scores at baseline and weeks 12 (A) and 24 (B) for sarilumab 150 mg and 200 mg+csDMARDs compared with placebo+csDMARDs.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment Ralf W. Sprengers, MD, Martin Teraa,

Spider plot of the unstandardised SF-36v2 subscales, comparing our HCM population with the mean for the general population (aged 45–54 years). Spider plot.

Characteristics of the included trials on non-pharmacological treatment. Characteristics of the included trials on non-pharmacological treatment. ASDAS,

Multivariable analysis of Clinical Disease Activity Index (CDAI) over time modelled with a cubic effect of time and adjusted for age, gender, disease duration,

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Patient disposition after 2 years of treatment.

Quality of life after aortic valve replacement with tissue and mechanical implants Artyom Sedrakyan, MD, Patricia Hebert, PhD, Viola Vaccarino, MD, PhD,

J. J. Smith, FRCS, A. M. Garratt, PhD, M. Guest, FRCS, R. M

Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Satisfaction with control of RA

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Mean profiles over 1 year from the observed Disease Activity Score 28 (DAS28) data for the methotrexate (MTX)-exposed patients after stratifying by predicted.

LPA groups display vastly different outcomes.

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

WOMAC (Western Ontario and McMaster Universities Arthritis Index) symptoms in the operated knee and contralateral knee over time and by treatment. WOMAC.

ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Kaplan-Meier failure curves with development of RA stratified by depression exposure. Kaplan-Meier failure curves with development of RA stratified by.

Presentation transcript:

SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations. SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations. Analyses were performed using the per-protocol population in AMBITION (TCZ, n=265; MTX, n=259) and the intention-to-treat population in ADACTA (TCZ, n=163; ADA, n=162). Normative values were defined as age-matched and gender-matched scores in a non-RA population without comorbid conditions. AMBITION population: PF: ≥78.8; RP: ≥79.1; BP: ≥67.4; GH: ≥68.2; VT: ≥56.6; SF: ≥81.7; RE: ≥85.0; MH: ≥72.9. ADACTA population: PF: ≥78.3; RP: ≥79.0; BP: ≥68.1; GH: ≥69.3; VT: ≥58.3; SF: ≥83.4; RE: ≥86.3; MH: ≥75.1. ADA, adalimumab; BP, bodily pain; GH, general health; MH, mental health; MTX, methotrexate; PF, physical functioning; RA, rheumatoid arthritis; RE, role-emotional; RP, role-physical; SF, social functioning; SF-36, Short Form-36; TCZ, tocilizumab; VT, vitality. Vibeke Strand et al. RMD Open 2017;3:e000496 Copyright © BMJ Publishing Group & EULAR. All rights reserved.